Here, Kosuke Minamihata, the Technical Support Manager for marketing at PeptiGrowth outlines the company’s efforts in developing peptide alternatives to conventional growth factors. PeptiGrowth is a subsidiary of the Mitsubishi Corporation, co-founded with PeptiDream in April 20. The company utilised PeptiDream's PDPS peptide discovery platform system to create synthetic peptides that mimicked the functions of conventional growth factors and cytokines. These peptides were marketed globally through Mitsubishi Corporation's extensive network.
The primary advantage of these synthetic peptides was their chemical synthesis, which ensured they were animal component-free and devoid of lot-to-lot activity variations and endotoxin contamination. This made them highly suitable for cellular applications due to their superior stability against heat and enzymatic degradation. Additionally, PeptiGrowth's large-scale synthetic facilities allowed for the production of peptides in significant quantities, reducing production costs and making them affordable for regenerative medicine, cell therapy, and cellular agriculture.
The presentation highlighted the issues associated with conventional growth factors, such as quality inconsistencies and contamination from animal components. PeptiGrowth's synthetic peptides addressed these issues by offering high stability and specificity. The company had launched seven products since April 2020, including alternatives to HGF, TGF beta 1 inhibitors, and BDNF, among others. Each product was designed to replicate the functions of its conventional counterpart while offering improved stability and activity.
The presentation concluded with a summary of the benefits of using PeptiGrowth's synthetic peptides, emphasising their cost-effectiveness, stability, and animal component-free nature. The company assured timely delivery of their products, leveraging their manufacturing capabilities in Japan. The presentation ended with a note of gratitude to the audience for their attention.
